Compare compounds

Pick up to 3 compounds to see protocols, mechanisms, study endpoints and safety findings side by side.

SLU-PP-332

Same goal

Include when printing

Only affects the printed page / PDF. The research-use-only notice always prints.

Protocol01

SLU-PP-332

Metabolic / Weight

Vials · 5 / 10 mg

01Protocol

Vials: 5 / 10 mg
Dosing data: Lab reference — not listed

02Quick calculator

03Mechanism of action

SLU-PP-332 is a synthetic small-molecule (not peptide) agonist of the estrogen-related receptors (ERRα/β/γ), which regulate mitochondrial and fatty-acid metabolism. It is described as an exercise mimetic.

04Study endpoints

In mice it increased energy expenditure and fatty-acid oxidation, reduced fat-mass gain and improved insulin sensitivity in metabolic-syndrome models.
In mouse pressure-overload heart failure, it improved ejection fraction, reduced fibrosis and increased survival.

05Safety & regulatory findings

Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
Evidence is from mouse studies; no human trials are cited.

06Citations

2 references · view